Capricor Therapeutics CAPR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | $0-100% | $11.13M-52.1% | $13.39M-50.7% | $17.36M-35.9% | ||
| $92.92M+60.8% | $84.45M+69.0% | $75.88M+67.3% | $67.33M+54.5% | $57.78M+44.9% | ||
| $27.02M+60.2% | $23.69M+59.3% | $21.94M+56.4% | $19.47M+43.4% | $16.86M+26.1% | ||
| $119.93M+60.7% | $108.14M+66.8% | $97.81M+64.7% | $86.8M+51.9% | $74.64M+40.2% | ||
| $119.93M+60.7% | $108.14M+66.8% | $97.81M+64.7% | $86.8M+51.9% | $74.64M+40.2% | ||
| -$119.93M-109% | -$108.14M-154% | -$86.68M-140% | -$73.41M-145% | -$57.28M-119% | ||
| $8.43M+243% | $6.26M+184% | $4.92M+150% | $3.66M+83.6% | $2.46M+37.9% | ||
| —— | —— | $4.69M+131% | $3.43M+67.0% | $2.22M+20.1% | ||
| —— | —— | —— | —— | -$235.28K— | ||
| —— | —— | —— | —— | -$54.74M— | ||
| —— | —— | —— | —— | $1.2K— | ||
| -$114.59M-108% | -$105.04M-160% | -$81.99M-140% | -$69.98M-150% | -$55.06M-126% | ||
| -$2.32-69.3% | -$2.26-96.5% | -$1.75-68.3% | -$1.59-74.7% | -$1.37-61.2% | ||
| -$2.32-69.3% | -$2.26-96.5% | -$1.75-68.3% | -$1.59-74.7% | -$1.37-61.2% | ||
| 195.3M+34.0% | 183.5M+39.6% | 172.3M+40.0% | 159.7M+37.9% | 145.8M+33.4% | ||
| 195.3M+34.0% | 183.5M+39.6% | 172.3M+40.0% | 159.7M+37.9% | 145.8M+33.4% | ||
| $8.43M+243% | $6.26M+184% | $4.92M+150% | $3.66M+83.6% | $2.46M+37.9% | ||
| -$116.66M-118% | -$105.79M-167% | -$81.24M-138% | -$68.74M-146% | -$53.56M-122% | ||
| -$2.07M-237% | -$743.8K-194% | $747.9K+4,503% | $1.23M+5,089% | $1.5M+607% | ||
| $41.08K+127% | $45.42K+508% | $36.08K+60.2% | $31.21K-16.9% | $18.09K-65.6% | ||
| -$119.93M-109% | -$108.14M-154% | -$86.68M-140% | -$73.41M-145% | -$57.28M-119% | ||
| -$117.91M-111% | -$106.25M-158% | -$84.92M-144% | -$71.78M-150% | -$55.78M-123% | ||
| -$117.91M-111% | -$106.25M-158% | -$84.92M-144% | -$71.78M-150% | -$55.78M-123% | ||
| -$119.93M-109% | -$108.14M-154% | -$86.68M-140% | -$73.41M-145% | -$57.28M-119% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Capricor Therapeutics profitable?
- Capricor Therapeutics is not currently profitable: it reported a net loss of $114.6M over the trailing twelve months, a -736.6% net margin.
- What is Capricor Therapeutics's earnings per share?
- Capricor Therapeutics's diluted EPS over the trailing twelve months is $-2.32.
- Where does Capricor Therapeutics's income statement data come from?
- Every line is extracted from Capricor Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.